コーパス検索結果 (left1)
通し番号をクリックするとPubMedの該当ページを表示します
1 PPSV23 uptake varies substantially by age and indication
2 ompared to mock immunization (PPSV23 = 9.19, PPSV23/PLY = 10.45, PLY = 8.71, Mock = 16.83; P = 0.0467
3 h pneumolysin toxoid (psiPLY), Pneumovax 23 (PPSV23; Merck, Whitehouse Station, NJ), or phosphate-buf
4 cal polysaccharide vaccine (Pneumovax(R) 23; PPSV23) or PLY protects against pneumococcal endophthalm
8 eading to pneumococcal infection), PCV13 and PPSV23 (Guillain-Barre syndrome), or PPSV23 (cellulitis)
9 t pneumococcal conjugate vaccine (PCV13) and PPSV23 (23-valent polysaccharide vaccine) for asplenic i
10 cted corneas were higher for the psiPLY- and PPSV23-immunized rabbits after infection with WU2, when
11 previous observational studies and to assess PPSV23 vaccine effectiveness in preventing IPD and the m
12 ealth Interview Survey, the authors assessed PPSV23 uptake in people with established and new indicat
15 s 18-64 years of age (18.6%) had established PPSV23 indications; adding asthma and smoking to the lis
16 Disease Control and Prevention criteria for PPSV23 administration, almost 50% of individuals had nev
18 % of people with established indications for PPSV23 and 17.4% of people with any indication (those pr
20 administration of PCV13 as a substitute for PPSV23 in current recommendations (ie, vaccination at ag
21 ions (PLY = 31.34% loss of retinal function, PPSV23/PLY = 27.44%) helped to significantly preserve re
22 ical severity compared to mock immunization (PPSV23 = 9.19, PPSV23/PLY = 10.45, PLY = 8.71, Mock = 16
24 al disease, but the lack of effectiveness of PPSV23 in protecting against all-cause HTP should be con
26 tered the combination immunization (5.29) or PPSV23 (5.29) with vancomycin treatment compared to cont
29 ividuals with beta-thalassemia, but previous PPSV23s affect the memory B-cell response in a dose- and
30 responses in HIV-infected adults with prior PPSV23 vaccination and CD4 cell counts >/= 200 cells/mm(
32 tors independently associated with receiving PPSV23, they used multivariable logistic regression and
34 a greater functional antibody response than PPSV23 in patients with COPD that persists for 2 years a
39 -valent pneumococcal polysaccharide vaccine (PPSV23) and 13-valent PCV within specified geographic an
40 -valent pneumococcal polysaccharide vaccine (PPSV23) and had CD4 cell counts >/= 200 cells/mm(3) and
41 -valent pneumococcal polysaccharide vaccine (PPSV23) for nonelderly adults with certain medical condi
42 -valent pneumococcal polysaccharide vaccine (PPSV23) for preventing all-cause pneumonia still undeter
43 -valent pneumococcal polysaccharide vaccine (PPSV23) protects against invasive disease in young healt
45 PCV13 vaccination was favored compared with PPSV23, but the analysis was sensitive to assumptions ab
46 </= 0.0010), whereas rabbits immunized with PPSV23 and Freund's adjuvant failed to show differences
48 nized with PBS and Freund's adjuvant or with PPSV23 and Freund's adjuvant at 48 hours after infection
WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。